Company intelligence / Profile preview

CB Therapeutics

Carlsbad, California, United Statescbthera.com ↗

Ownership: Private
Development stage: Other

Overview

CB Therapeutics has developed a proprietary yeast platform enabling the sustainable production of pure cannabinoids, psychedelic therapeutics, and other bio-identical molecules. The company supplies these to industries including neuroscience research, nutraceuticals, cosmetics, cannabis markets, and food technology. They have achieved 99%+ purity in rare cannabinoid production using patent-pending techniques but do not appear to have clinical-stage pharmaceutical programs yet[1][3].

Therapeutic areas: NeurologyPsychiatryMetabolic DisordersOther
Modalities: Small moleculeBiologic (via biosynthetic production)Psychedelic therapeutics (biosynthesized)Cannabinoids (biosynthesized)
Industry: Non-Drug Biotech

Partnerships

atai Life Sciences (partnership focused on meeting unmet needs in mental health)

Beyond the preview

Go deeper on CB Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB Therapeutics.

Explore the full profile